Treatment of Relapsed/Refractory Hodgkin Lymphoma with Brentuximab Vedotin

A clinical practice guideline for patients with relapsed/refractory Hodgkin’s lymphoma. The guideline examines treatment with brentuximab vedotin. Outcomes of interest include progression-free and overall survival.